TipRanks
Advertisement
Advertisement
Akero Therapeutics announces new findings from SYMMETRY, HARMONY trials
PremiumThe FlyAkero Therapeutics announces new findings from SYMMETRY, HARMONY trials
12M ago
Akero Therapeutics’ Phase 3 Study on Efruxifermin: A Potential Game-Changer for NASH/MASH Treatment
Premium
Company Announcements
Akero Therapeutics’ Phase 3 Study on Efruxifermin: A Potential Game-Changer for NASH/MASH Treatment
12M ago
Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
Premium
Company Announcements
Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
12M ago
Akero Therapeutics downgraded to Hold from Buy at Clear Street
PremiumThe FlyAkero Therapeutics downgraded to Hold from Buy at Clear Street
1y ago
Akero Therapeutics Acquired by Novo Nordisk for $5.2B
Premium
Company Announcements
Akero Therapeutics Acquired by Novo Nordisk for $5.2B
1y ago
Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Premium
The Fly
Akero Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
1y ago
Cautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties
PremiumRatingsCautious Hold Rating on Akero Therapeutics Amid Novo Nordisk Acquisition and Regulatory Uncertainties
1y ago
Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin’s Clinical Trajectory
Premium
Ratings
Cautious Hold Rating on Akero Therapeutics Amid Acquisition Interest and Uncertainties in Efruxifermin’s Clinical Trajectory
1y ago
Akero Therapeutics downgraded to Hold from Buy at Jefferies
Premium
The Fly
Akero Therapeutics downgraded to Hold from Buy at Jefferies
1y ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―